 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other May 6 Calls Today's Calls |
| Call Details | |||
| EPIX Pharmaceuticals, Inc. Earnings Conference Call (Q1 2008) Tue, May 6, 2008, 10:00 am Eastern
| |||
| About EPIX Pharmaceuticals, Inc. (NasdaqGM:EPIX) | Other Calls | ||
| EPIX Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery technology for Alzheimer’s disease, cardiovascular disease, and cognitive impairment. The company’s therapeutic product candidates in development include PRX-08066 that is in Phase IIa clinical trials for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease; PRX-03140, which is in Phase IIa clinical trials for the treatment of Alzheimer's disease; PRX-00023 that is in Phase IIb clinical trials for the treatment of depression; and PRX-07034, which is in Phase Ib clinical trials for the treatment of obesity and cognitive impairment associated with schizophrenia and Alzheimer’s disease. Its imaging agents comprise Vasovist, an injectable intravascular contrast agent that provides enhanced imaging of the vascular system using magnetic resonance angiography. EPIX Pharmaceuticals has collaborations with SmithKline Beecham Corporation; Amgen, Inc.; Cystic Fibrosis Foundation Therapeutics, Incorporated; and Bayer Schering Pharma AG, Germany. The company was founded in 1988 as Metacorp, Inc. and changed its name to METASYN, Inc. in 1989. Further, it changed its name to EPIX Medical, Inc. in 1996; and to EPIX Pharmaceuticals Inc. in 2004. The company is headquartered in Lexington, Massachusetts. | |||
More Info: | |||
